EDESA BIOTECH, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
EDESA BIOTECH, INC. (EDSA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.92% for the 12-month period ending 2024-09-30, per its 10-K filed 2025-12-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2025-12-12
- EDESA BIOTECH, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-12-31 was 4.92%, a 35.91% increase year-over-year.
- EDESA BIOTECH, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-12-31 was 3.62%, a 1067.74% increase year-over-year.
- EDESA BIOTECH, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2021-12-31 was 0.31%, a 0.00% change year-over-year.
- EDESA BIOTECH, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2020-12-31 was 0.31%.
- EDESA BIOTECH, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.92%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2024-09-30 | 4.92% 10-K · filed 2025-12-12 | |||
| 2024-06-30 | 4.92% 10-Q · filed 2025-08-08 | |||
| 2024-03-31 | 4.92% 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | 4.92% 10-Q · filed 2025-02-14 | |||
| 2022-12-31 | 3.62% 10-Q · filed 2023-02-10 | |||
| 2021-12-31 | 0.31% 10-Q · filed 2022-02-14 | |||
| 2020-12-31 | 0.31% 10-Q · filed 2021-02-16 | |||
| 2020-06-30 | 1.45% 10-Q · filed 2021-08-13 | |||
| 2020-03-31 | 1.45% 10-Q · filed 2021-05-14 | |||
| 2019-09-30 | 1.98% 10-K · filed 2020-12-07 | |||
| 2019-06-30 | 1.98% 10-Q · filed 2020-08-12 | |||
| 2019-03-31 | 1.98% 10-Q · filed 2020-05-15 | |||
| 2018-12-31 | 1.98% 10-Q · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |